Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer
Gregory T. Wolf(University of Michigan), Francis P. Worden(Georgetown University), Avraham Eisbruch(University of Michigan–Ann Arbor), Mark E. Prince(University of Michigan), Jeremy M. G. Taylor(RAND Corporation), Carol R. Bradford(The Ohio State University), Emily L. Bellile(University of Michigan), Lisa A. Peterson(University of Minnesota), Norman D. Hogikyan(Michigan Medicine), Susan Urba(Michigan Medicine), Douglas B. Chepeha(University of Michigan), Scott A. McLean(National Health Service), Theodoros N. Teknos(University Hospitals Seidman Cancer Center), Jeffery Moyer(Michigan Medicine)
Cited by 44
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Validation of an instrument to measure voice-related quality of life (V-RQOL)
|Journal of Voice|1999|1.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653